For licensed clinics onlyRefrigerated lines shipped cold
1-800-630-9757Open hoursMonday to Friday, 9am to 6pm ETBook a call with MWS

Nexplanon Irregular Bleeding After 2 Years: Evaluation Steps

Bleeding that turns irregular late in the life of an etonogestrel implant is usually a continuation of the device’s unpredictable bleeding pattern, not evidence that it has failed or run out. Contraceptive efficacy does not track with the bleeding pattern. When a patient reports nexplanon irregular bleeding after 2 years, the clinical job is to separate expected pattern drift from a finding that needs a workup: pregnancy, infection, cervical or endometrial pathology, or a drug interaction that lowers hormone levels.

That distinction matters because bleeding complaints drive most early removals. A five-minute structured assessment often keeps a satisfied patient on a highly effective method.

The Short Version

  • Pattern change is common: irregular, infrequent, prolonged or absent bleeding can all appear at any point during use.
  • Efficacy is not signaled by bleeding: spotting does not mean the implant has stopped working.
  • Always exclude pregnancy first, including ectopic pregnancy, whatever the timing.
  • New-onset bleeding after a stable interval deserves history, exam and targeted testing rather than reassurance alone.
  • Confirm the implant is palpable at every bleeding visit and document the arm, site and date.

Is Nexplanon Irregular Bleeding After 2 Years Expected?

Often, yes. Nexplanon is a single-rod subdermal implant containing 68 mg of etonogestrel, made radiopaque with barium sulfate, and approved in the United States for pregnancy prevention for up to three years; the prescribing information is the controlling reference for duration, interactions and handling (see the current labeling through the FDA’s Drugs@FDA labeling database). The label is explicit that bleeding patterns are unpredictable and that the pattern seen in the first three months broadly predicts, but does not guarantee, the pattern later on.

Serum etonogestrel concentrations decline gradually across the use period while remaining sufficient to suppress ovulation in most users. That slow decline, combined with a thin and asynchronously shed endometrium, is the usual explanation for spotting that appears or worsens in year two or year three. Superficial endometrial vessels are fragile and bleed at different times rather than in a coordinated monthly shed.

Brown discharge, spotting and “constant” bleeding

Brown discharge is almost always old blood that has oxidized before leaving the uterus. Patients describe it as staining rather than flow, and it frequently follows a stretch of amenorrhea (no bleeding). Light intermittent spotting fits the same mechanism. What does not fit is genuinely heavy or truly continuous bleeding: flow that soaks through protection hourly, passes large clots, causes fatigue or lightheadedness, or persists for many weeks without a break. Those presentations get an evaluation, not reassurance.

Why it matters: most late-onset spotting is benign, but the few cases that are not look identical over the phone.

Sorting Expected Pattern Change From Red Flags

The useful triage question is not “how long has she had the implant” but “what changed, and what else is going on.” Bleeding that has been erratic since insertion carries a different weight than bleeding that begins abruptly after eighteen stable months. The table below summarizes how common presentations are usually read in practice.

PresentationUsual interpretationClinic action
Intermittent spotting or brown discharge, no other symptomsConsistent with expected implant bleeding patternExclude pregnancy, confirm implant palpable, counsel and offer symptomatic options
Amenorrhea followed by new irregular bleedingCommon, but overlaps with pregnancy and infectionPregnancy test, sexual history, consider chlamydia and gonorrhea testing
Heavy or prolonged bleeding with fatigue or pallorPossible anemia or structural causeCBC and ferritin, pelvic exam, consider pelvic ultrasound
Postcoital or persistent malodorous bleeding, pelvic painCervical or upper genital tract pathologySpeculum exam, STI testing, cervical screening per current guideline
Bleeding starting soon after a new medicationPossible enzyme-inducing drug interactionFull medication and supplement review, including herbal products

Hepatic enzyme inducers deserve a specific question. Rifampin, carbamazepine, phenytoin, some other anticonvulsants and St. John’s wort can lower etonogestrel levels, which may produce breakthrough bleeding and may reduce contraceptive effectiveness. The labeling addresses these interactions directly and is the right place to check an individual agent.

A Practical Evaluation Sequence

Work the problem in a fixed order so nothing is skipped when the schedule is tight. The same sequence applies whether the complaint is nexplanon irregular bleeding after 2 years or new spotting at twelve months.

  1. Exclude pregnancy. Urine or serum hCG, with a low threshold for considering ectopic pregnancy if there is pain or syncope.
  2. Take a focused history. Onset, duration, volume, postcoital bleeding, pain, discharge, new medications, missed implant removal date.
  3. Palpate the implant. Confirm presence, length and position in the non-dominant upper arm; document what you felt.
  4. Examine. Speculum and bimanual exam to look at the cervix and assess for tenderness or an enlarged uterus.
  5. Test selectively. Chlamydia and gonorrhea when risk factors are present, CBC for heavy or prolonged bleeding, cervical screening if the patient is due.
  6. Image when indicated. Pelvic ultrasound for suspected fibroids, polyps or retained products; endometrial evaluation when age and risk factors warrant it.
  7. Reassess the method. If the bleeding is tolerable and benign, continuation is reasonable; if not, discuss alternatives without pressure.

Document a negative workup clearly. Patients often return, and a legible record of what has already been excluded prevents duplicate testing.

Management and Counseling Options Backed by Guidance

For unscheduled bleeding during implant use with no pathology found, published guidance describes short symptomatic courses rather than immediate removal. The U.S. Selected Practice Recommendations for Contraceptive Use outline options including a short course of NSAIDs, and, for patients who are medically eligible for estrogen, a brief course of a low-dose combined oral contraceptive or estrogen; the current recommendations are maintained by the CDC’s contraceptive practice recommendations. Eligibility screening still applies before any estrogen-containing option is offered.

Counseling carries at least as much weight as any prescription. Bleeding irregularity is the most frequently cited reason for discontinuation in the implant literature, and expectations set at insertion predict tolerance later. Three points tend to land well with patients:

  • Unpredictable is normal: some users have almost no bleeding, others spot intermittently for years.
  • Spotting is not failure: the implant continues to prevent pregnancy through the labeled duration regardless of pattern.
  • Come back for change: heavy flow, pain, fever, or bleeding after intercourse are reasons to be seen, not to wait.

Give patients a specific escalation threshold rather than “call if it gets worse.” Soaking a pad or tampon hourly for several hours, dizziness, fainting, severe one-sided pelvic pain, or a positive pregnancy test all warrant same-day assessment or emergency care.

Removal, Replacement, and the Non-Palpable Implant

Bleeding complaints frequently surface near the end of the approved use period, which makes the visit a natural checkpoint for removal or replacement planning. Use the documented insertion date, not the patient’s recollection. Published data have examined effectiveness beyond the labeled three years, but any use past the labeled duration is off-label and should be framed that way in both counseling and the chart.

If the implant cannot be felt, do not proceed blindly. The prescribing information directs localization before removal, typically with a high-frequency linear ultrasound transducer or MRI; because the rod is radiopaque, two-dimensional X-ray or CT can also localize it. When imaging fails, the label describes confirming presence with an etonogestrel blood level through the manufacturer, and referral to a clinician experienced in deep removals is appropriate. Attempted exploration without localization risks neurovascular injury in the upper arm.

Stocking, Storage, and Documentation

Implants are prescription-only devices supplied as a single sterile, preloaded applicator, so inventory handling is straightforward but unforgiving of sloppy records. Store at controlled room temperature as stated in the labeling, keep each unit in its unopened sterile pouch until the moment of insertion, and rotate stock by expiration date. Med Wholesale Supplies is a wholesale supplier of aesthetic, orthopedic and medical products to clinics, hospitals and medical professionals, operating since 2013; whatever the source, confirm that incoming lots match the packing documentation and that cold-chain-free storage conditions were maintained in transit.

Record keeping is the part audits examine. For every insertion, capture the lot number, expiration date, arm used, insertion site measured from a fixed landmark, and the patient-held card with the planned removal date. For every bleeding visit, capture palpation findings, pregnancy test result, tests ordered, counseling given and the follow-up plan.

Checklist for the Bleeding Visit

  • Pregnancy test documented, including ectopic consideration if pain is present.
  • Implant palpated and findings recorded; imaging arranged if non-palpable.
  • Insertion date verified against the chart and the patient card.
  • Medication and supplement review for enzyme-inducing agents.
  • Speculum exam and STI testing where history or symptoms support it.
  • CBC and ferritin for heavy or prolonged bleeding.
  • Cervical screening status confirmed and updated if due.
  • Symptomatic options and continuation preferences discussed and charted.
  • Written escalation thresholds given to the patient.

Handled this way, most cases of nexplanon irregular bleeding after 2 years resolve into a short reassurance visit with a clean negative workup, and the small number that do not are caught early. Where evidence is thin, such as bleeding management beyond the labeled duration, say so to the patient and defer to current national guidance and the manufacturer’s instructions for use.

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.

Frequently asked questions

Does brown discharge on the implant after two years mean something is wrong?

Usually not. Brown discharge is typically old blood that oxidized before leaving the uterus, and it commonly follows a stretch of light bleeding or amenorrhea during implant use. It is consistent with the unpredictable endometrial shedding seen with etonogestrel. It still warrants basic assessment: exclude pregnancy, confirm the implant is palpable, and review new medications. Discharge that is malodorous, accompanied by pelvic pain or fever, or follows intercourse points toward infection or cervical pathology and should prompt an exam, sexually transmitted infection testing and cervical screening if due.

Does irregular bleeding mean the implant has stopped working?

No. Bleeding pattern does not indicate contraceptive effectiveness with the etonogestrel implant. Hormone levels decline gradually across the approved use period while generally remaining adequate to suppress ovulation, so spotting can appear in year one, two or three without any loss of protection. The exceptions worth checking are a non-palpable implant, use beyond the labeled duration, and medications that induce hepatic enzymes, such as rifampin, certain anticonvulsants or St. John’s wort, which may lower hormone levels. A pregnancy test remains the first step at any bleeding visit.

When should a patient with implant-related bleeding be seen urgently?

Give patients concrete thresholds. Same-day assessment is appropriate for bleeding that soaks a pad or tampon hourly for several hours, large clots, dizziness, fainting or shortness of breath. Severe one-sided pelvic pain with a positive pregnancy test requires emergency evaluation for ectopic pregnancy. Fever, foul-smelling discharge or pelvic tenderness suggests infection and needs prompt review. Bleeding after intercourse, or bleeding that continues for many weeks without a break, should be evaluated within days rather than managed by phone reassurance alone.

What should a clinic do if the implant cannot be palpated at a bleeding visit?

Stop and localize before attempting removal. The prescribing information directs imaging first, generally a high-frequency linear ultrasound transducer or MRI; because the rod contains barium sulfate it is radiopaque, so X-ray or CT can also identify it. If imaging does not locate the device, the label describes confirming its presence with an etonogestrel blood level arranged through the manufacturer. Refer to a clinician experienced in deep implant removal, document the failed palpation and the imaging performed, and advise backup contraception until the situation is resolved.

How should implant stock be stored and documented in the clinic?

Store units at controlled room temperature as specified in the labeling, keep each applicator sealed in its sterile pouch until insertion, and rotate inventory by expiration date. Check incoming lots against packing documentation on receipt. For each insertion, record the lot number, expiration date, arm used, the measured insertion site and the planned removal date, and issue the patient card. For each subsequent bleeding visit, record palpation findings, pregnancy test results, tests ordered and counseling provided so repeat visits do not duplicate work.

Frequently asked questions

Bleeding can return because progestin-only implants may affect the uterine lining in changing ways over time. A patient can have months of no bleeding, then spotting, brown discharge, or a period-like episode. That pattern may still be medication-related. Clinics should still assess duration of use, pregnancy risk, bleeding volume, pain, fever, discharge, and anemia symptoms before labeling it benign.

Irregular bleeding alone does not prove implant failure or reduced contraceptive effect when the device is still within its labeled duration. Bleeding pattern is not a reliable measure of efficacy. If the implant is past labeled use, the insertion date is uncertain, pregnancy symptoms are present, or pelvic pain occurs, clinics should evaluate those issues directly rather than relying on bleeding pattern.

Urgent assessment is more appropriate when bleeding is very heavy, causes dizziness or fainting, includes severe or unilateral pelvic pain, occurs with fever or abnormal discharge, or is linked to a positive pregnancy test. Symptoms suggesting anemia, such as marked fatigue, pallor, shortness of breath, or functional decline, also warrant closer evaluation. Light intermittent spotting without systemic symptoms is usually less urgent but still needs clear follow-up instructions.

Document the insertion date, time since placement, onset of the current pattern, number of bleeding days, estimated volume, clots, pain, discharge, fever, pregnancy symptoms, medication changes, and relevant testing. Record counseling about expected variability, red flags, and whether the plan is observation, targeted testing, treatment, referral, or removal discussion. Clear notes make later visits easier to compare.

Brown discharge can represent older blood and may occur with implant-related spotting. Color alone does not determine risk. The clinical context matters more: amount, duration, recurrence, pregnancy risk, pelvic pain, fever, discharge, postcoital bleeding, and anemia symptoms. If brown discharge is heavy, persistent, painful, or associated with infection or pregnancy concern, it should be evaluated rather than dismissed.

About this article

Written by

Med Wholesale Supplies Editorial Team

The Med Wholesale Supplies editorial team writes practical, clinician-facing guides on aesthetic injectables, orthopaedic and medical supplies, product selection and clinic workflow, sourced from product documentation, regulators and peer-reviewed literature.

Medical disclaimerThe information published on Med Wholesale Supplies is provided for informational purposes only and should not be considered medical advice, diagnosis, or treatment guidance. Healthcare decisions should always be made in consultation with a licensed physician, pharmacist, or other qualified healthcare professional. If you are experiencing a medical emergency, call 911 or seek emergency care immediately.

Editorial policyMed Wholesale Supplies is committed to publishing clear, accurate, and medically reviewed content for readers and healthcare audiences. Our editorial standards are intended to support responsible, evidence-informed communication and a high level of content quality. Please visit our Editorial Standards page to learn more about how our content is developed and reviewed.

From our catalog

Related products

Shop all products

Keep reading

More articles on this topic

All articles